Source: Paradigm Biopharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Paradigm Biopharmaceuticals (PAR) begins dosing subjects in phase 3 of its clinical trial to test its Zilosul treatment for knee osteoarthritis pain
  • The aim of the study is to measure the change in pain and function when receiving the injection of Zilosul, as opposed to the placebo
  • The study is currently enrolling subjects in eight sites across Australia, as well as 21 of 56 selected sites in the US
  • A key focus for the company has been clinical trial site activation, which has enabled a large pool of potential candidates to be screened at activated sites
  • Shares are trading 4.47 per cent higher at $1.29 each at 12:30 pm AEST

Paradigm Biopharmaceuticals (PAR) has started dosing subjects in phase 3 of its clinical trial to test its Zilosul drug in treatment of pain associated with knee osteoarthritis.

The aim of the study is to measure the change in pain and function when receiving the injection of Zilosul, as opposed to the placebo.

The study is currently enrolling subjects in eight sites across Australia, as well as 21 of 56 selected sites in the US.

A key focus for the company has been clinical trial site activation, which has enabled a large pool of potential candidates to be screened at activated sites.

Paradigm said it will continue site activations in the US, while also starting its search for sites in the UK and Europe.

“The Paradigm clinical team has been working tirelessly to initiate and activate sites throughout the US and we are seeing a large number of subjects entering the screening phase throughout the US,” Chief Medical Officer and interim CEO, Dr Donna Skerrett said.

“We look forward to continuing the strong momentum in the phase 3 program and reporting important recruitment milestones to our shareholders.”

Shares were trading 4.47 per cent higher at $1.29 each at 11:30 am AEST.

PAR by the numbers
More From The Market Herald
Countplus (ASX:CUP) - Incoming CEO, Hugh Humphrey

" Hugh Humphrey appointed CEO of Countplus (ASX:CUP)

Investment services company CountPlus (ASX:CUP) has appointed Hugh Humphrey as the company's CEO, effective July 1.

" ASX employee tests positive for Covid-19

The ASX says an employee has contracted Covid-19.

" ASIC launches official investigation into ASX market outage

The ASX has confirmed today it is officially under investigation from the Australian Securities and Investments…

" ASX sheds more light on last week’s market tech failure

The Australian Securities Exchange has shed some more light on the nature of last week's market…